Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 13/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.36 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.35 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.35 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.35 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.35 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.35 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4929353 | 1.00 | P2RX7 (0.36) | P2RX7MAP4K4PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL4925056 | 0.80 | P2RX7 (0.52) | P2RX7ACACB | |
| SCHEMBL4916876 | 0.79 | P2RX7 (0.47) | P2RX7ACACB | |
| SCHEMBL4918026 | 0.76 | P2RX7 (0.55) | P2RX7PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4929348 | 0.76 | P2RX7 (0.71) | P2RX7 | |
| SCHEMBL1978384 | 0.74 | CHRNB2 (0.48) | — | |
| SCHEMBL1978385 | 0.74 | CHRNB2 (0.48) | — | |
| SCHEMBL18291259 | 0.74 | NPC1 (0.34) | MAP4K4 | |
| SCHEMBL25311546 | 0.73 | EGLN1 (0.42) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL25311537 | 0.73 | EGLN1 (0.42) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058309-A1 | Novel Compounds 171 | ASTRAZENECA AB | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058309-A1 | Novel Compounds 171 | C1R, F12, ADRA1D | P2RX7 309/4885MAP4K4 3567/4885PRKAB2 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.